Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 7:30 AM EDTPositive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers
Provides Update to Certain Trials based on Expanding Clinical Experience
Conference Call Scheduled for today at 8:30 a.m. ET
NEWTON, Mass., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
"Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was... More
